The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma
Open accessAbstract
Background and Aim: The Child–Pugh classification has some non‐objective factors, with chronic hepatitis indistinguishable from early liver cirrhosis in Child–Pugh A. We retrospectively evaluated the efficacy of albumin–bilirubin (ALBI) grade, which has been proposed as a new classification for hepatic function, for grading hepatocellular carcinoma (HCC) patients based on hepatic function and predicting their prognosis. Method: From 2000 to 2014, 2584 naïve HCC [69.0 ± 9.8 years old, 1850 men, 734 female, Child–Pugh class A:B:C = 1871:558:155] were enrolled. TNM staging was determined using the classification of the Liver Cancer Study Group of Japan and ALBI grade, instead of Child–Pugh classification (ALBI with TNM score: ALBI‐T score) (Table 1), and is similar to the Japan Integrated Staging (JIS) score. We retrospectively compared ALBI‐T and JIS scores in these patients. Results: Of patients classified as Child–Pugh A (n = 1871), 1285 with 5 points were divided into 858 with ALBI grade 1 and 427 with grade 2, while 586 with 6 points were divided into 53 with grade 1 and 533 with grade 2. The ratio of ALBI grade 2 patients with a Child–Pugh score of 6 points (91.0%) was similar to that of those with 7 points (91.8%). Patients with a lower ALBI‐T score (0–5 points) showed a better median survival time than those with a corresponding lower JIS score [137.7:83.2:53.4:27.4:5.0:1.4 vs 97.6:74.9:39.7:15.0:4.0:1.0 months]. Conclusion: Albumin–bilirubin grade was found to be superior for distinguishing patients with better hepatic function. ALBI‐T scoring may be a better total prognostic scoring system for predicting survival of Japanese patients with HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Cited by
Management of Hepatocellular Carcinoma: A Review
Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2022.7989 · Cited by 763
Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Self-citationPinato, D. J., Sharma, R., Allara, E., Yen, C., Arizumi, T., Kubota, K., Bettinger, D., Jang, J. W., Smirne, C., Kim, Y. W., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.008 · Cited by 413
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., Mo, S., Sypsa, V., Guha, I. N., Kumada, T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.025 · Cited by 364
Self-citationHiraoka, A., Michitaka, K., Kumada, T., Izumi, N., Kadoya, M., Kokudo, N., Kubo, S., Matsuyama, Y., Nakashima, O., Sakamoto, M., et al. (2017) · Liver Cancer · doi:10.1159/000479984 · Cited by 331
Self-citation
Metadata
- Authors
- Hiraoka, A., Kumada, T., Michitaka, K., Toyoda, H., Tada, T., Ueki, H., Kaneto, M., Aibiki, T., Okudaira, T., Kawakami, T., Kawamura, T., Yamago, H., Suga, Y., Miyamoto, Y., Tomida, H., Azemoto, N., Mori, K., Miyata, H., Ninomiya, T., & Kawasaki, H.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2016-04-28
- Volume
- 31
- Issue
- 5
- Pages
- 1031-1036
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W2192368460
- Cited by
- 245
- References
- 2
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.